Under the current agreement, Molbio will have the rights to commercialize, market and sell PROMILLESS under its own brand name globally
Molbio Diagnostics has announced its partnership with Finnish innovation company, Testi Technologies, to manufacture its flagship product PROMILLESS – a saliva-based diagnostics test to measure body alcohol content.
PROMILLESS is an easy to use, low cost, saliva based self-diagnostics test that has been developed together with VTT (Technical Research Centre of Finland) is a CE approved class 1 device that is patented worldwide. The self-test alcohol strip recognises alcohol content from saliva and determines if the alcohol content is above or below the indicated threshold level. The self-test will be available over the counter for use by consumers and law enforcement.
Tommi Vaskivuo, Chairman, Testi Technologies said, “This partnership unites Testi Technologies’ innovation in enzymatic test technology with Molbio Diagnostics’ technological strength, production capabilities and extensive global network. Together, we are set to revolutionise healthcare diagnostics, blending our strengths to offer advanced, accessible solutions. This collaboration is a powerful step towards making a significant impact on global health.”
Under the current agreement, Molbio will have the rights to commercialize, market and sell PROMILLESS under its own brand name globally.
Sriram Natarajan, Chief Executive Officer, Molbio Diagnostics says, “We are delighted to be a joint development, manufacturing and go to market partner of Testi Technologies. Their non-invasive enzymatic testing technology enables simple, rapid and accurate detection of analytes in saliva, by just touching the test stick to tongue. The current test for alcohol, the upcoming test for glucose and many more human and veterinary tests in the pipeline will prove to be revolutionary.”